Breast cancer diagnostics

Breast cancer diagnostics

Empowering clinical confidence

Roche Tissue Diagnostics delivers a comprehensive suite of ­validated immunohistochemistry and in situ hybridisation diagnostic solutions for breast cancer — so you can ­deliver the right test, with clinical confidence.

Our breast cancer predictive diagnostic ­offerings (HER2 IHC and ISH, ER, PR) in combination with our supporting diagnostic assays (Ki-67, p120 and E-cadherin) are fully automated on VENTANA BenchMark systems, which reduces the time to result and resources required compared to ­manual or semiautomated solutions.

Your benefit


Clinical confidence

  • High accuracy and clinical confidence in a short turnaround time to ­identify ­patients other assays can miss Analytical superiority
  • Specific and sensitive rabbit monoclonal antibodies, probes and powerful detection systems


Testing efficiency

  • Comprehensive breast cancer solution 
  • Fully automated assays, with digital ­pathology and workflow solutions


Product characteristics


INFORM HER2 Dual ISH DNA Probe Cocktail assay

  • Brightfield detection allows evaluation of HER2 gene status with morphological context


HER2 (4B5) Rabbit Monoclonal Antibody

  • Clinical confidence with a world-class HER2 rabbit monoclonal antibody


Breast carcinoma INFORM HER2 Dual ISH DNA Probe Cocktail ­non-amplified; magnification: 40X


Breast carcinoma HER2 (4B5) positive Score: 3+; magnification: 40X.